Does anyone have information about the GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine?

While reading the current NCRN CLL clinical trials map I noticed an interesting addition in set up for CLL/SLL in supportive care alongside the many new trials. Does anyone know more about this particular vaccine?

ncrndev.org.uk/downloads/Tr...

“NCRN436: Safety, immunogenicity & efficacy of GSK Biologicals Herpes Zoster HZ/su candidate vaccine”

Shingles - live vaccines and the shingles vaccine is a popular topic as CLL/SLL patients are directed to avoid live vaccines. Herpes Zoster reaction is a common enemy for the CLL/SLL community especially during and after treatment.

Also at UK Trials Gateway: ukctg.nihr.ac.uk/trialdetai...

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Clinicaltrials.gov: clinicaltrials.gov/show/NCT...

Last edited by

2 Replies

oldestnewest
  • The vaccine has been around since 2007 in various clinical trials as GSK1437173A

    gsk-clinicalstudyregister.c...

    The vaccine is based on QS-21...

    QS-21 Stimulon adjuvant has become a critical component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases, and appears to be essential for several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. Currently, QS-21 is being studied in clinical trials in approximately 17 vaccine indications, of which four are in Phase 3 studies. These include RTS,S for malaria, MAGE-A3 for non-small cell lung cancer, MAGE-A3 for melanoma and Zoster Herpes for shingles. In addition, a QS-21-containing vaccine candidate is in Phase 2 trials for the treatment of Alzheimer’s disease. Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy**. QS-21 represents the most clinically advanced adjuvant.

    agenusbio.com/products/qs21...

    agenusbio.com/docs/factshee...

    ncbi.nlm.nih.gov/pmc/articl...

  • Thanks Chris

    This is really interesting reading. A very useful plant extract. from creating soda suds to enhancing cancer vaccines.

    Thanks for pointing me to the GSK registry very useful. Is the ad

    gsk-clinicalstudyregister.c...

    Can you explain why this is the first exclusion?

    • Subject diagnosed with chronic lymphocytic leukaemia (CLL) who is receiving only oral cancer therapy (subject receiving intra-venous cancer therapy for CLL or intra-venous cancer therapy in combination with oral therapy may be enrolled).

You may also like...